March 2021 Affinity Group Meeting
You’re invited to join the Clinical TMS Society for the March 23, 2021 Affinity Group Meeting.
CLINICAL TMS RESEARCH COMMITTEE AFFINITY GROUPS:
Description: The Research Committee would like to help members form Affinity Groups to pursue their interests. Affinity Groups can serve to help members e-meet periodically by Skype and in person at the Annual Meeting to share information and clinical experiences, write papers, or even organize a project. If you would like to identify a group of CTMSS members who share your interests in studying a specialized topic such as off-label treatments (e.g., tinnitus, chronic pain), specialized protocols (e.g., accelerated TMS), or any focused research of clinical question, then we want to hear from you. We will send out a notice to the society to help you identify like-minded individuals. Intested in starting an affinity group? Email email@example.com with 3-4 sentences about your idea for a group.
Date: March 23, 2021
Time: 5:00 pm PST / 8:00 pm EST
This meeting is for current members only.
CURRENT AFFINITY GROUP BREAKOUT SESSIONS:
TMS and Addiction Affinity Group:
- Chair: TBD
- Group Description: We know beyond doubt the benefit of rTMS in treating depression and OCD; and we can envisage the potential that the future holds for this therapy in the field of treatment of substance use disorders (SUD); be it due to the effect of rTMS on craving or the reward pathways resulting from SUD. We, as people of science, are determined to scrutinise the evidence available to ensure that our research committee guides the general knowledge and informs clinicians' decisions in deciding about the effect and use of this treatment in the delicate art of treating SUD. Our ultimate aim is to help better improve the treatments available for SUD patients at a time when the epidemic of use of some drugs is a great threat to some of our communities.
TMS and Sleep Disorders Affinity Group:
- Chairs: Debra Stultz, MD
- Group Description: An increasing number of TMS reports are available documenting improvement of sleep disorders with TMS in areas such as insomnia with and without depression, restless Leg syndrome, sleep disruption in Parkinson’s, insomnia secondary to chronic pain, substance abuse related insomnia, and in Narcolepsy to name a few. Studies have been described using rTMS, dTMS, and Theta Burst treatment. Documented improvement has been demonstrated with TMS on the Insomnia Severity Index, the Pittsburgh Sleep Quality Index, the Athens Insomnia Scale, the Parkinson’s Disease Sleep Scale, the International RLS Rating Scale, the Epworth Sleepiness Scale, PSG findings, EEG findings, and Actigraphy. The goal of our group will be to increase the awareness of sleep related TMS studies available to the society and to create a cohesive group of individuals to review new data on TMS in sleep with suggestions for broader research projects in the future, encouraging other TMS providers to more specifically monitor for sleep in their research projects and report the effects on sleep to contribute to our increasing body of evidence of TMS benefits, and to eventually help obtain insurance approval for TMS in the area of sleep.
TMS and Autism Affinity Group:
- Chairs: Marco Marcolin, MD, PhD, Bianca Bellini, MD, Manuel Cassanova, MD
- Group description: Autism Spectrum Disorder (ASD) is a multifactorial group of neurodevelopmental disorders whose treatment relies primarily on symptomatic interventions. Research on transcranial magnetic stimulation (TMS) in ASD is still at an early stage. Still, many research studies, with limited numbers of high-functioning individuals, have proven to normalize executive functions, repetitive behaviors, dysatunomic symptoms, and brainwave oscillatory abnormalities. Benefits have been achieved with little in terms of side effects. This affinity discussion group aims to increase awareness as to this potential therapeutic intervention while broadening research collaboration. We aim to foster concerted international efforts promoting a phase III clinical trial, discuss the best stimulation parameters for this patient population, examine the need for booster shots after TMS therapy, and help screen for potential baseline biomarkers that may be able to predict outcome.
TMS and Data Collection Affinity Group:
- Chairs: Gonzalo Laje, MD, Angela Phillips, PhD, LICSW, Martha Koo, MD
- Group Description: The TMS & Data Collection Affinity Group will lead efforts to create and implement guidelines for clinical TMS data collection, with relevant, associated clinical data. These efforts may be presented individually or in an effort to pool larger data sets among collaborating TMS clinics and clinicians, in attempts to inform CTMSS society meeting content (e.g. conference talks, posters, abstracts, etc.), and/or the greater scientific community (e.g. academic journal publications). The overall aim of this group is to organize ways to utilize past, present and future TMS data collection in order to advance the scientific understanding of TMS, including but not limited to, factors affecting TMS outcomes, expansion of TMS clinical applications, assessment/comparison of specific TMS protocols, and factors affecting recurrence of illness.
TMS & Ketamine Affinity Group:
- Chairs: Steve Best, MD, Robert Pollack, MD, Rocky Sullivan, DO
- Group Description: Interest is rising in combining TMS with ketamine to harness the synergistic effect of these two conventional interventions for treatment-resistant depression. We are proposing an affinity group where members can meet to share clinical cases to better establish treatment protocols, share data, and advocate for this breakthrough treatment.
Private Practice TMS: Clinical and Business Affinity Group:
- Chair: John Robertson, MD
- Group Description: Share our private practice experiences in order to enhance our success treating patients.
TMS Mechanisms Affinity Group:
- Chair: Joshua Brown, MD
- Group Description: The “TMS Mechanisms” affinity group is dedicated understanding how TMS changes the brain in a durable and therapeutic way. Such an understanding spans networks to molecules, in both animals and humans, and with both clinical and pre-clinical models. A mechanistic understanding is essential for patient education; optimization of current treatments; and expansion of investigative treatments.